Pmv Pharmaceuticals Inc - Asset Resilience Ratio
Pmv Pharmaceuticals Inc (PMVP) has an Asset Resilience Ratio of 81.59% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Pmv Pharmaceuticals Inc to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Pmv Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Pmv Pharmaceuticals Inc total assets.
Liquid Assets Composition Over Time
This chart breaks down Pmv Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore how much of Pmv Pharmaceuticals Inc's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $66.96 Million | 81.59% |
| Total Liquid Assets | $66.96 Million | 81.59% |
Asset Resilience Insights
- Very High Liquidity: Pmv Pharmaceuticals Inc maintains exceptional liquid asset reserves at 81.59% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Pmv Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Pmv Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Pmv Pharmaceuticals Inc (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Pmv Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.31% | $74.96 Million | $116.56 Million | -2.91pp |
| 2024-12-31 | 67.22% | $128.58 Million | $191.29 Million | +1.64pp |
| 2023-12-31 | 65.58% | $165.35 Million | $252.15 Million | +16.46pp |
| 2022-12-31 | 49.11% | $132.76 Million | $270.31 Million | +11.51pp |
| 2021-12-31 | 37.61% | $124.70 Million | $331.57 Million | -- |
| 2020-12-31 | 0.00% | $0.00 | $365.53 Million | -- |
| 2019-12-31 | 27.38% | $28.21 Million | $103.03 Million | -22.42pp |
| 2018-12-31 | 49.80% | $31.60 Million | $63.46 Million | -- |
About Pmv Pharmaceuticals Inc
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule therapies targeting p53 mutations and other p53-related cancers in the United States. It develops rezatapopt, a selective structural corrector of p53 Y220C mutations in Phase 2 clinical trials for tumor agnostic diseases. The company was formerly known as PJ Pharmaceuticals, Inc. an… Read more